<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36507670</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2165-0497</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>Microbiology spectrum</Title><ISOAbbreviation>Microbiol Spectr</ISOAbbreviation></Journal><ArticleTitle>Protease-Independent Production of Poliovirus Virus-like Particles in Pichia pastoris: Implications for Efficient Vaccine Development and Insights into Capsid Assembly.</ArticleTitle><Pagination><StartPage>e0430022</StartPage><MedlinePgn>e0430022</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e04300-22</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/spectrum.04300-22</ELocationID><Abstract><AbstractText>The production of enterovirus virus-like particles (VLPs) that lack the viral genome have great potential as vaccines for a number of diseases, such as poliomyelitis and hand, foot, and mouth disease. These VLPs can mimic empty capsids, which are antigenically indistinguishable from mature virions, produced naturally during viral infection. Both in infection and <i>in vitro</i>, capsids and VLPs are generated by the cleavage of the P1 precursor protein by a viral protease. Here, using a stabilized poliovirus 1 (PV-1) P1 sequence as an exemplar, we show the production of PV-1 VLPs in Pichia pastoris in the absence of the potentially cytotoxic protease, 3CD, instead using the porcine teschovirus 2A (P2A) peptide sequence to terminate translation between individual capsid proteins. We compare this to protease-dependent production of PV-1 VLPs. Analysis of all permutations of the order of the capsid protein sequences revealed that only VP3 could be tagged with P2A and maintain native antigenicity. Transmission electron microscopy of these VLPs reveals the classic picornaviral icosahedral structure. Furthermore, these particles were thermostable above 37°C, demonstrating their potential as next generation vaccine candidates for PV. Finally, we believe the demonstration that native antigenic VLPs can be produced using protease-independent methods opens the possibility for future enteroviral vaccines to take advantage of recent vaccine technological advances, such as adenovirus-vectored vaccines and mRNA vaccines, circumventing the potential problems of cytotoxicity associated with 3CD, allowing for the production of immunogenic enterovirus VLPs <i>in vivo</i>. <b>IMPORTANCE</b> The widespread use of vaccines has dramatically reduced global incidence of poliovirus infections over a period of several decades and now the wild-type virus is only endemic in Pakistan and Afghanistan. However, current vaccines require the culture of large quantities of replication-competent virus for their manufacture, thus presenting a potential risk of reintroduction into the environment. It is now widely accepted that vaccination will need to be extended posteradication into the foreseeable future to prevent the potentially catastrophic reintroduction of poliovirus into an immunologically naive population. It is, therefore, imperative that novel vaccines are developed which are not dependent on the growth of live virus for their manufacture. We have expressed stabilized virus-like particles in yeast, from constructs that do not require coexpression of the protease. This is an important step in the development of environmentally safe and commercially viable vaccines against polio, which also provides some intriguing insights into the viral assembly process.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sherry</LastName><ForeName>Lee</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4367-772X</Identifier><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swanson</LastName><ForeName>Jessica J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grehan</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huijun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uchida</LastName><ForeName>Mai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Reading, School of Biological Sciences, Reading, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Ian M</ForeName><Initials>IM</Initials><Identifier Source="ORCID">0000-0002-7738-2516</Identifier><AffiliationInfo><Affiliation>University of Reading, School of Biological Sciences, Reading, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stonehouse</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0003-1146-5519</Identifier><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowlands</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-4742-9272</Identifier><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microbiol Spectr</MedlineTA><NlmUniqueID>101634614</NlmUniqueID><ISSNLinking>2165-0497</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000676904">Komagataella pastoris</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002213" MajorTopicYN="N">Capsid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pichia pastoris</Keyword><Keyword MajorTopicYN="N">poliomyelitis</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword><Keyword MajorTopicYN="N">virus-like particle</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>12</Day><Hour>11</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36507670</ArticleId><ArticleId IdType="pmc">PMC9927490</ArticleId><ArticleId IdType="doi">10.1128/spectrum.04300-22</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polio Now–GPEI. https://polioeradication.org/polio-today/polio-now/. Accessed 15 March 2022.</Citation></Reference><Reference><Citation>Zambon M, Martin J. 2018. Polio eradication: next steps and future challenges. Eurosurveillance 23. doi:10.2807/1560-7917.ES.2018.23.47.1800625.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2018.23.47.1800625</ArticleId><ArticleId IdType="pmc">PMC6341938</ArticleId><ArticleId IdType="pubmed">30482261</ArticleId></ArticleIdList></Reference><Reference><Citation>Two out of three wild poliovirus strains eradicated. https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated. Accessed 22 April 2022.</Citation></Reference><Reference><Citation>Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. 2015. Polio vaccination: past, present and future. Future Microbiol 10:791–808. doi:10.2217/fmb.15.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.15.19</ArticleId><ArticleId IdType="pubmed">25824845</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor P. 2009. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27:2649–2652. doi:10.1016/j.vaccine.2009.02.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.02.071</ArticleId><ArticleId IdType="pubmed">19428874</ArticleId></ArticleIdList></Reference><Reference><Citation>Jegouic S, Joffret M-L, Blanchard C, Riquet FB, Perret C, Pelletier I, Colbere-Garapin F, Rakoto-Andrianarivelo M, Delpeyroux F. 2009. Recombination between polioviruses and co-circulating coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses. PLoS Pathog 5:e1000412. doi:10.1371/journal.ppat.1000412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000412</ArticleId><ArticleId IdType="pmc">PMC2669712</ArticleId><ArticleId IdType="pubmed">19412342</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene SA, Ahmed J, Datta SD, Burns CC, Quddus A, Vertefeuille JF, Wassilak SGF. 2019. Progress toward polio eradication—Worldwide, January 2017–March 2019. MMWR Morb Mortal Wkly Rep 68:458–462. doi:10.15585/mmwr.mm6820a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6820a3</ArticleId><ArticleId IdType="pmc">PMC6532951</ArticleId><ArticleId IdType="pubmed">31120868</ArticleId></ArticleIdList></Reference><Reference><Citation>Te Yeh M, Bujaki E, Dolan PT, Smith M, Wahid R, Konz J, Weiner AJ, Bandyopadhyay AS, Van Damme P, De Coster I, Revets H, Macadam A, Andino R. 2020. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe 27:736–751.e8. doi:10.1016/j.chom.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lulla V, Dinan AM, Hosmillo M, Chaudhry Y, Sherry L, Irigoyen N, Nayak KM, Stonehouse NJ, Zilbauer M, Goodfellow I, Firth AE. 2019. An upstream protein-coding region in enteroviruses modulates virus infection in gut epithelial cells. Nat Microbiol 4:280–292. doi:10.1038/s41564-018-0297-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0297-1</ArticleId><ArticleId IdType="pmc">PMC6443042</ArticleId><ArticleId IdType="pubmed">30478287</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuthill TJ, Groppelli E, Hogle JM, Rowlands DJ. 2010. Picornaviruses, p 43–89. In Current topics in microbiology and immunology.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018333</ArticleId><ArticleId IdType="pubmed">20397067</ArticleId></ArticleIdList></Reference><Reference><Citation>Molla A, Harris KS, Paul AV, Shin SH, Mugavero J, Wimmer E. 1994. Stimulation of poliovirus proteinase 3Cpro-related proteolysis by the genome-linked protein VPg and its precursor 3AB. J Biol Chem 269:27015–27020. doi:10.1016/S0021-9258(18)47119-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)47119-0</ArticleId><ArticleId IdType="pubmed">7929442</ArticleId></ArticleIdList></Reference><Reference><Citation>Jore J, De Geus B, Jackson RJ, Pouwels PH, Enger-Valk BE. 1988. Poliovirus protein 3CD is the active protease for processing of the precursor protein P1 in vitro. J Gen Virol 69:1627–1636. doi:10.1099/0022-1317-69-7-1627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-69-7-1627</ArticleId><ArticleId IdType="pubmed">2839599</ArticleId></ArticleIdList></Reference><Reference><Citation>Kräusslich HG, Nicklin MJ, Lee CK, Wimmer E. 1988. Polyprotein processing in picornavirus replication. Biochimie 70:119–130. doi:10.1016/0300-9084(88)90166-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0300-9084(88)90166-6</ArticleId><ArticleId IdType="pubmed">2840974</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P, Liu Y, Ma H-C, Paul AV, Wimmer E. 2014. Picornavirus morphogenesis. Microbiol Mol Biol Rev 78:418–437. doi:10.1128/MMBR.00012-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.00012-14</ArticleId><ArticleId IdType="pmc">PMC4187686</ArticleId><ArticleId IdType="pubmed">25184560</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogle JM, Chow M, Filman DJ. 1985. Three-dimensional structure of poliovirus at 2.9 A resolution. Science 229:1358–1365. doi:10.1126/science.2994218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2994218</ArticleId><ArticleId IdType="pubmed">2994218</ArticleId></ArticleIdList></Reference><Reference><Citation>Basavappa R, Filman DJ, Syed R, Flore O, Icenogle JP, Hogle JM. 1994. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 Å resolution. Protein Sci 3:1651–1669. doi:10.1002/pro.5560031005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.5560031005</ArticleId><ArticleId IdType="pmc">PMC2142606</ArticleId><ArticleId IdType="pubmed">7849583</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bouvier GL. 1955. The modification of poliovirus antigens by heat and ultraviolet light. Lancet 269:1013–1016. doi:10.1016/s0140-6736(55)93435-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(55)93435-8</ArticleId><ArticleId IdType="pubmed">13272322</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bouvier GL. 1959. Poliovirus D and C antigens: their differentiation and measurement by precipitation in agar. Br J Exp Pathol 40:452–463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2082302</ArticleId><ArticleId IdType="pubmed">14414842</ArticleId></ArticleIdList></Reference><Reference><Citation>Beale AJ, Mason PJ. 1962. The measurement of the D-antigen in poliovirus preparations. J Hyg (Lond) 60:113–121. doi:10.1017/s002217240003936x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s002217240003936x</ArticleId><ArticleId IdType="pmc">PMC2134470</ArticleId><ArticleId IdType="pubmed">13866112</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. 1984. Human hepatitis B vaccine from recombinant yeast. Nature 307:178–180. doi:10.1038/307178a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/307178a0</ArticleId><ArticleId IdType="pubmed">6318124</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MA, Finch J, Crawford L, Tommasino M. 1995. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 206:126–135. doi:10.1016/s0042-6822(95)80027-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0042-6822(95)80027-1</ArticleId><ArticleId IdType="pubmed">7831768</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith J, Lipsitch M, Almond JW. 2011. Vaccine production, distribution, access, and uptake. Lancet 378:428–438. doi:10.1016/S0140-6736(11)60478-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)60478-9</ArticleId><ArticleId IdType="pmc">PMC3164579</ArticleId><ArticleId IdType="pubmed">21664680</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombaut B, Jore JP. 1997. Immunogenic, non-infectious polio subviral particles synthesized in Saccharomyces cerevisiae. J Gen Virol 78:1829–1832. doi:10.1099/0022-1317-78-8-1829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-78-8-1829</ArticleId><ArticleId IdType="pubmed">9266976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansardi DC, Porter DC, Morrow CD. 1991. Coinfection with recombinant vaccinia viruses expressing poliovirus P1 and P3 proteins results in polyprotein processing and formation of empty capsid structures. J Virol 65:2088–2092. doi:10.1128/JVI.65.4.2088-2092.1991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.65.4.2088-2092.1991</ArticleId><ArticleId IdType="pmc">PMC240068</ArticleId><ArticleId IdType="pubmed">1848318</ArticleId></ArticleIdList></Reference><Reference><Citation>Viktorova EG, Khattar SK, Kouiavskaia D, Laassri M, Zagorodnyaya T, Dragunsky E, Samal S, Chumakov K, Belov GA. 2018. Newcastle disease virus-based vectored vaccine against poliomyelitis. J Virol 92. doi:10.1128/JVI.00976-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00976-18</ArticleId><ArticleId IdType="pmc">PMC6096817</ArticleId><ArticleId IdType="pubmed">29925653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahar MW, Porta C, Fox H, Macadam AJ, Fry EE, Stuart DI. 2021. Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. NPJ Vaccines 6:5. doi:10.1038/s41541-020-00267-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-00267-3</ArticleId><ArticleId IdType="pmc">PMC7794334</ArticleId><ArticleId IdType="pubmed">33420068</ArticleId></ArticleIdList></Reference><Reference><Citation>Bräutigam S, Snezhkov E, Bishop DHL. 1993. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology 192:512–524. doi:10.1006/viro.1993.1067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1993.1067</ArticleId><ArticleId IdType="pubmed">8380663</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Ma S, Huang Y, Chen F, Chen L, Ding D, Zheng Y, Li H, Xiao J, Feng J, Peng T. 2019. Virus-like particle vaccines for poliovirus types 1, 2, and 3 with enhanced thermostability expressed in insect cells. Vaccine 37:2340–2347. doi:10.1016/j.vaccine.2019.03.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.03.031</ArticleId><ArticleId IdType="pubmed">30922699</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsian J, Fox H, Bahar MW, Kotecha A, Fry EE, Stuart DI, Macadam AJ, Rowlands DJ, Lomonossoff GP. 2017. Plant-made polio type 3 stabilized VLPs—a candidate synthetic polio vaccine. Nat Commun 8:245. doi:10.1038/s41467-017-00090-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00090-w</ArticleId><ArticleId IdType="pmc">PMC5557999</ArticleId><ArticleId IdType="pubmed">28811473</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry L, Grehan K, Snowden JS, Knight ML, Adeyemi OO, Rowlands DJ, Stonehouse NJ. 2020. Comparative molecular biology approaches for the production of poliovirus virus-like particles using Pichia pastoris. mSphere 5:e00838–19. doi:10.1128/mSphere.00838-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00838-19</ArticleId><ArticleId IdType="pmc">PMC7067596</ArticleId><ArticleId IdType="pubmed">32161150</ArticleId></ArticleIdList></Reference><Reference><Citation>Barco A, Feduchi E, Carrasco L. 2000. Poliovirus protease 3Cpro kills cells by apoptosis. Virology 266:352–360. doi:10.1006/viro.1999.0043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1999.0043</ArticleId><ArticleId IdType="pubmed">10639321</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox H, Knowlson S, Minor PD, Macadam AJ. 2017. Genetically thermo-stabilised, immunogenic poliovirus empty capsids; a strategy for non-replicating vaccines. PLoS Pathog 13:e1006117. doi:10.1371/journal.ppat.1006117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006117</ArticleId><ArticleId IdType="pmc">PMC5245777</ArticleId><ArticleId IdType="pubmed">28103317</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Alzahrani J, Sherry L, Stacey M, Rowlands DJ, Ranson NA, Stonehouse NJ. 2021. Structural insight into Pichia pastoris fatty acid synthase. Sci Rep 11. doi:10.1038/s41598-021-89196-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-89196-2</ArticleId><ArticleId IdType="pmc">PMC8105331</ArticleId><ArticleId IdType="pubmed">33963233</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss M, Schotte L, Karunatilaka KS, Filman DJ, Hogle JM. 2017. Cryo-electron microscopy structures of expanded poliovirus with VHHs sample the conformational repertoire of the expanded state. J Virol 91. doi:10.1128/JVI.01443-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01443-16</ArticleId><ArticleId IdType="pmc">PMC5244317</ArticleId><ArticleId IdType="pubmed">27852863</ArticleId></ArticleIdList></Reference><Reference><Citation>Lua LHL, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg APJ. 2014. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng 111:425–440.</Citation><ArticleIdList><ArticleId IdType="pubmed">24347238</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Lee S-R, Li L-H, Park H-J, Park J-H, Lee KY, Kim M-K, Shin BA, Choi S-Y. 2011. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 6:e18556. doi:10.1371/journal.pone.0018556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0018556</ArticleId><ArticleId IdType="pmc">PMC3084703</ArticleId><ArticleId IdType="pubmed">21602908</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Chen O, Wall JBJ, Zheng M, Zhou Y, Wang L, Ruth Vaseghi H, Qian L, Liu J. 2017. Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Sci Rep 7:1–9. doi:10.1038/s41598-017-02460-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-02460-2</ArticleId><ArticleId IdType="pmc">PMC5438344</ArticleId><ArticleId IdType="pubmed">28526819</ArticleId></ArticleIdList></Reference><Reference><Citation>Gullberg M, Polacek C, Bøtner A, Belsham GJ. 2013. Processing of the VP1/2A junction is not necessary for production of foot-and-mouth disease virus empty capsids and infectious viruses: characterization of “self-tagged” particles. J Virol 87:11591–11603. doi:10.1128/JVI.01863-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01863-13</ArticleId><ArticleId IdType="pmc">PMC3807367</ArticleId><ArticleId IdType="pubmed">23966400</ArticleId></ArticleIdList></Reference><Reference><Citation>Triantafilou K, Triantafilou M, Takada Y, Fernandez N. 2000. Human parechovirus 1 utilizes integrins αvβ3 and αvβ1 as receptors. J Virol 74:5856–5862. doi:10.1128/jvi.74.13.5856-5862.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.74.13.5856-5862.2000</ArticleId><ArticleId IdType="pmc">PMC112080</ArticleId><ArticleId IdType="pubmed">10846065</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann H, Eggers HJ, Nelsen-Salz B. 1997. Cell attachment and mouse virulence of echovirus 9 correlate with an RGD motif in the capsid protein VP1. Virology 233:149–156. doi:10.1006/viro.1997.8601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1997.8601</ArticleId><ArticleId IdType="pubmed">9201224</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakeel S, Seitsonen JJT, Kajander T, Laurinmäki P, Hyypiä T, Susi P, Butcher SJ. 2013. Structural and functional analysis of coxsackievirus A9 integrin α v β 6 binding and uncoating. J Virol 87:3943–3951. doi:10.1128/JVI.02989-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02989-12</ArticleId><ArticleId IdType="pmc">PMC3624221</ArticleId><ArticleId IdType="pubmed">23365426</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi P-Y, Türeci Ö, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Şahin U, Gruber WC. 2020. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 383:2439–2450. doi:10.1056/NEJMoa2027906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2027906</ArticleId><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Aboagye J, Adams K, Ali A, Allen E, Allison JL, Anslow R, Arbe-Barnes EH, Babbage G, Baillie K, Baker M, Baker N, Baker P, Baleanu I, Ballaminut J, Barnes E, Barrett J, Bates L, Batten A, Oxford COVID Vaccine Trial Group , et al. 2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396:467–478. doi:10.1016/S0140-6736(20)31604-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31604-4</ArticleId><ArticleId IdType="pmc">PMC7445431</ArticleId><ArticleId IdType="pubmed">32702298</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, Dinnon KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Wu K, Henry C, Bahl K, Garcia-Dominguez D, Ma LZ, Renzi I, Kong WP, Schmidt SD, Wang L, Zhang Y, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanan E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Stevens LJ, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, et al. 2020. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586:567–571. doi:10.1038/s41586-020-2622-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2622-0</ArticleId><ArticleId IdType="pmc">PMC7581537</ArticleId><ArticleId IdType="pubmed">32756549</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P-C, Mahmood T. 2012. Western blot: technique, theory, and trouble shooting. N Am J Med Sci 4:429–434. doi:10.4103/1947-2714.100998.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1947-2714.100998</ArticleId><ArticleId IdType="pmc">PMC3456489</ArticleId><ArticleId IdType="pubmed">23050259</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer C, Knauert F, Bushar G, Klutch M, Lundquist R, Quinnan GV. 1989. Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies. J Biol Stand 17:137–150. doi:10.1016/0092-1157(89)90004-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-1157(89)90004-8</ArticleId><ArticleId IdType="pubmed">2541133</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD, Ferguson M, Katrak K, Wood D, John A, Howlett J, Dunn G, Burke K, Almond JW. 1991. Antigenic structure of chimeras of type 1 and type 3 polioviruses involving antigenic sites 2, 3 and 4. J Gen Virol 72:2475–2481. doi:10.1099/0022-1317-72-10-2475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-72-10-2475</ArticleId><ArticleId IdType="pubmed">1717641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson M, Wood DJ, Minor PD. 1993. Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol 74:685–690. doi:10.1099/0022-1317-74-4-685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-74-4-685</ArticleId><ArticleId IdType="pubmed">7682250</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682. doi:10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671–675. doi:10.1038/nmeth.2089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2089</ArticleId><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>